Alimera Sciences Reports First Quarter 2023 Results
Consolidated Net Revenue of $13.5 Million Up 14% vs. First Quarter of 2022 Global End…
Year: 2023
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline
Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with…
Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
– Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy…
Ikena Oncology Announces $40 Million Underwritten Offering
BOSTON, May 15, 2023 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted…
Bavarian Nordic Completes Acquisition of Travel Vaccine Portfolio from Emergent BioSolutions
COPENHAGEN, Denmark, May 15, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that it…
POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer
POINT further strengthens supply chain with $10 million investment in Ionetix Alpha Corp. INDIANAPOLIS and…
PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results
Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to…
BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”…
POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
U.S. FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC in April…
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
― Appointed Alex C. Sapir CEO & President, effective July 1st, 2023 ― ― On…
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement…
Avalo to Present at ATS 2023 Respiratory Innovation Summit
WAYNE, Pa. and ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq:…
Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA
OTL-200 Biologics License Application (BLA) submission completion anticipated in mid-2023 Libmeldy revenue and commercial patients…
First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference
BOCA RATON, Fla., May 15, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (NASDAQ: FWBI)…
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
— Industry veteran brings more than 20 years of experience; will assume role effective July…
Trevena Reports First Quarter 2023 Results and Provides Business Update
OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company’s China partner…
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with…
Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update
Two ongoing Phase 2 studies of bitopertin in EPP; initial safety and efficacy data from…
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results
Safety data indicate that repeated subcutaneous injections of 25 mg CTI-1601 were generally well tolerated…
Oxford Biomedica launches TetraVecta – the next generation lentiviral vector system
Oxford Biomedica launches TetraVectaTM – the next generation lentiviral vector system Oxford, UK – 15…